275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
Amit Bardia, K. Punie, Carlos H. Barrios, A. Schneeweiss, X. Zhai, D.H. Huynh, N. Vaksman, Chiajen Lai, Sara M. Tolaney
Topics & Concepts
MedicineTriple-negative breast cancerOncologyInternal medicineBreast cancerCancerCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer Research